Combination therapy using IL-2 and anti-CD25 results in augmented natural killer cell-mediated antitumor responses.
about
Advantages and clinical applications of natural killer cells in cancer immunotherapyPositive and negative regulation by NK cells in cancerInteraction between natural killer cells and regulatory T cells: perspectives for immunotherapyThe 4q27 locus and prostate cancer risk.Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein.Allogeneic natural killer cells for refractory lymphomaRecombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808The interaction between regulatory T cells and NKT cells in the liver: a CD1d bridge links innate and adaptive immunity.Increased antitumor effects using IL-2 with anti-TGF-β reveals competition between mouse NK and CD8 T cells.Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation?Present and Future of Allogeneic Natural Killer Cell TherapyDepletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia.Natural killer cells and malignant haemopathies: a model for the interaction of cancer with innate immunity.Immunotherapeutic modulation of the suppressive liver and tumor microenvironments.Natural killer cell immune escape in acute myeloid leukemia.Natural killer cell receptors: alterations and therapeutic targeting in malignancies.Defective STAT1 activation associated with impaired IFN-γ production in NK and T lymphocytes from metastatic melanoma patients treated with IL-2.Role of regulatory T cells in acute myeloid leukemia patients undergoing relapse-preventive immunotherapy.Prophylactic use of low-dose interleukin-2 and the clinical outcomes of hematopoietic stem cell transplantation: A randomized study.
P2860
Q26999224-7D264B18-AC49-46BF-8A49-2EDE4F0B4E92Q27004658-FEE69BED-4285-467A-A07B-0CDFFE32D4CDQ27008625-8B8DE551-6AA2-4F14-8228-5C1C38CFBDDAQ33534461-BF3317D4-D925-4B30-AD93-E78488C0F1D7Q33781150-DADE0D53-E953-42DD-9B0A-5EA3738CBD1BQ33850138-6D641788-0EB5-41A7-84AF-4F409FD2EADDQ34069811-5485CB8B-1085-4466-B87C-D0AA3573AC3CQ34071745-F7832447-C6B5-4D45-A48D-63F7C456C18BQ34563034-10645330-3931-42C5-AB0A-52EA50DDA4FAQ35553553-29AECCF3-0347-4414-94A0-135DD70DF7E5Q35677351-9AC21955-22F2-404B-B520-0809269A987DQ37412327-C08EF3AD-411F-4D31-8982-E43DE33BD92FQ37779043-C364552D-00EB-427E-8A12-26C2B0F7C9EEQ37829504-4BFE7920-D4B5-45F0-9197-0D26B935D216Q37996816-FE48B4D8-B874-4D81-B3F5-6563A3426826Q38587627-2B4CE036-8149-47E8-B4A3-A48B42B18108Q41667279-2AE9E23C-2162-4F9A-A79A-0D0D0D4A5530Q42683573-29056B24-E542-4116-B6F1-8DD00EDD35ABQ42968779-C3512AB8-4C21-44A3-8A47-810CDCBDFCCC
P2860
Combination therapy using IL-2 and anti-CD25 results in augmented natural killer cell-mediated antitumor responses.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Combination therapy using IL-2 ...... -mediated antitumor responses.
@en
Combination therapy using IL-2 ...... -mediated antitumor responses.
@nl
type
label
Combination therapy using IL-2 ...... -mediated antitumor responses.
@en
Combination therapy using IL-2 ...... -mediated antitumor responses.
@nl
prefLabel
Combination therapy using IL-2 ...... -mediated antitumor responses.
@en
Combination therapy using IL-2 ...... -mediated antitumor responses.
@nl
P2093
P2860
P1476
Combination therapy using IL-2 ...... -mediated antitumor responses.
@en
P2093
Isabel Barao
Maite Alvarez
Patricia A Taylor
William H D Hallett
William J Murphy
P2860
P304
P356
10.1016/J.BBMT.2008.08.001
P577
2008-10-01T00:00:00Z